ReviewFEMS microbiology reviews2024
The role of human extracellular matrix proteins in defining Staphylococcus aureus biofilm infections.
Review in FEMS microbiology reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 51 citations in OpenAlex.
- Dodonaea viscosa-mediated zinc oxide nanoparticles exhibit antibacterial, anti-biofilm, and anti-virulence activity against methicillin-resistant Staphylococcus aureus.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Pilot Study on the Use of Low-Field Nuclear Magnetic Resonance as a Noninvasive Tool for Monitoring Mucus in Obstructive Lung Diseases.International journal of molecular sciences · 2026Article
- Stage-Dependent Antibiofilm Effects of UVA Combined with Cinnamaldehyde AgainstAntioxidants (Basel, Switzerland) · 2026Article
- Host soluble plasma factors increase dual-species Staphylococcus epidermidis and Candida albicans biofilm biomass without enhancing stress tolerance.Scientific reports · 2026Article
- Controlling Staphylococcus aureus skin infections by targeting biofilm and virulence properties using FDA-approved antiseptics and skin care products.Folia microbiologica · 2026Article
- Detection to Disruption: A Comprehensive Review of Bacterial Biofilms and Therapeutic Advances.Antibiotics (Basel, Switzerland) · 2026Review
- Investigating the Sharing ofPathogens (Basel, Switzerland) · 2026Article
- Bacterial biosurfactant-reinforced chitooligosaccharide/polyvinyl alcohol hydrogels accelerate methicillin-resistantAsian journal of pharmaceutical sciences · 2026Article
- Article
- Collagen binding adhesin restricts Staphylococcus aureus skin infection.Nature communications · 2026Article
- Antimicrobial photodynamic therapy withFrontiers in cellular and infection microbiology · 2026Article
- Case Report: Moxibustion-induced burns leading to disseminated methicillin-resistantFrontiers in endocrinology · 2026Article
- A single amino acid substitution in Fibronectin Binding protein A (FnBPA) governs Staphylococcus aureus virulence via host transglutaminase-mediated fibrin crosslinking.PLoS pathogens · 2025Article
- Intracellular survival ofVirulence · 2025Review
- Review
- Antimicrobial Activity ofAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Review
- Extracellular adherence proteins reduce matrix porosity and enhanceInfection and immunity · 2025Article
- PDMS biointerfaces featuring honeycomb-like well microtextures designed for a pro-healing environment.RSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Twenty to forty one percent of the world's population is either transiently or permanently colonized by the Gram-positive bacterium, Staphylococcus aureus. In 2017, the CDC designated methicillin-resistant S. aureus (MRSA) as a serious threat, reporting ∼300 000 cases of MRSA-associated hospitalizations annually, resulting in over 19 000 deaths, surpassing that of HIV in the USA. S. aureus is a proficient biofilm-forming organism that rapidly acquires resistance to antibiotics, most commonly methicillin (MRSA). This review focuses on a large group of (>30) S. aureus adhesins, either surface-associated or secreted that are designed to specifically bind to 15 or more of the proteins that form key components of the human extracellular matrix (hECM). Importantly, this includes hECM proteins that are pivotal to the homeostasis of almost every tissue environment [collagen (skin), proteoglycans (lung), hemoglobin (blood), elastin, laminin, fibrinogen, fibronectin, and fibrin (multiple organs)]. These adhesins offer S. aureus the potential to establish an infection in every sterile tissue niche. These infections often endure repeated immune onslaught, developing into chronic, biofilm-associated conditions that are tolerant to ∼1000 times the clinically prescribed dose of antibiotics. Depending on the infection and the immune response, this allows S. aureus to seamlessly transition from colonizer to pathogen by subtly manipulating the host against itself while providing the time and stealth that it requires to establish and persist as a biofilm. This is a comprehensive discussion of the interaction between S. aureus biofilms and the hECM. We provide particular focus on the role of these interactions in pathogenesis and, consequently, the clinical implications for the prevention and treatment of S. aureus biofilm infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.